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Objectives: To present and discuss the case of a diabetic patient admitted with acidoketotic
coma, with inner canthus tumefaction due to mucormycosis.
Case study: A 38-year-old diabetic man was admitted with acidoketotic coma and poor general
health status. Clinical examination found right inner canthus tumefaction and mucopurulent rhi-
norrhea. Endoscopy of the nasal fossae found medial meatus sphaceluses. Sinus CT scan found a
bilateral ethmoid inﬁltrating and osteolytic infectious process. Emergency endoscopic bilateral
ethmoidectomy was performed. Mucormycosis was diagnosed, and liposomal amphotericin B
was administered intravenously for 1month then replaced by posaconazole. The patient was
followed up monthly; the antifungal treatment was terminated after 8months, the disease
appearing to have resolved.
Comments and conclusion: Mucormycosis is one of the most rapidly fatal fungal infections.
Facial and cerebral CT scan is essential and is systematically abnormal in case of sinonasal
mucormycosis. Emergency multidisciplinary treatment should address the diabetes and include
rapid surgical debridement and effective antifungal medication. The reference antifungal is
amphotericin B, to be administered at maximal dose (3 to 5mg/kg per day). Posaconazole,
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Introduction
Mucormycosis is one of the most rapidly fatal fungal
infections in humans. It occurs in diabetic patients in aci-
doketotic coma or in profound immunodepression. The
most characteristic clinical feature is rhino-orbito-cerebral
involvement. The present case exempliﬁes the therapeutic
and diagnostic issues raised by this pathology.
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ase study
38-year-old man was admitted with acidoketotic coma.
wenty days later, when his diabetic state was stabilized,
ainful inﬂammatory tumefaction appeared in the right
emiface, with deterioration of general health status and
ilateral mucopurulent rhinorrhea without fever. Biological
nalysis found an inﬂammatory biological syndrome (hyper-
eukocytosis at 15G/l, CRP at 12mg/l). Facial CT scan found
ight ethmoid sinusitis, and the patient was transferred to
NT. Nasal fossae endoscopy found bilateral diffuse whitish
laments, which were sampled for biopsy, and an aspect of
phaceluses in the medial meatuses. CT control at 48 hours
.









































Figure 2 Axial CT slice. Lysis of base of skull, ethmoid papyra-
















cigure 1 Axial CT slice. Bilateral ethmoid opacity, lysis of
ight papyraceous lamina and lachrymal bone, right osteitis of
asal bone.
ound an osteolytic inﬁltrating infectious process (bilateral
thmoid opacity and lysis of the right papyraceous lam-
na and lachrymal bone and osteitis of the nasal bone)
Fig. 1). Cerebral and sinus MRI conﬁrmed the absence of
rain lesion. Mucormycosis was suspected, and endonasal
urgery was immediately undertaken without waiting for the
iopsy results, comprising right ethmoidectomy and right
edial meatotomy, and left anterior ethmoidectomy with
natomopathologic, biologic and mycologic sampling. Direct
xamination found large mycelial ﬁlaments with a crumpled
spect associated with signs of ischemic necrosis, conﬁrm-
ng diagnosis. IV liposomal amphotericin B (3mg/kg per day)
as initiated. Evolution was favorable as of the ﬁrst week,
ith cessation of pain and regression of the hemifacial
dema. After 1month, the IV treatment was replaced by oral
osaconazole (400mg twice daily). At 2months, on read-
ission for surveillance, the clinical symptomatology had
esolved, but sinus CT found persistent lysis of the skull
ase, ethmoid papyraceous lamina and right lachrymal bone
Fig. 2). Endonasal samples were free of mycotic agents,
nd the patient therefore underwent no further complemen-
ary surgery. He was followed up monthly for 1 year (Fig. 3).
ntifungal medication was withdrawn after 8months.
iscussion
pidemiologically, the factors predisposing to mucormy-
osis are acidoketosis (in diabetes or renal insufﬁciency)
nd immunodepression (organ transplant, HIV infection,
orticotherapy, deferoxamine treatment, prolonged neu-
ropenia) [1—3]. Some rare cases have been reported in
atients without obvious immune deﬁciency [4]. Mucormy-
osis is most frequently sinonasal (39%), then pulmonary
24%), cutaneous (19%), cerebral (9%), gastro-intestinal
7%), other (6%) or disseminated (6%) [5]. The entry point
s usually respiratory, by spore inhalation, or more rarely
y digestion or percutaneous inoculation. Inter-human
ontamination has never been reported [6]. Incidence is





migure 3 Axial CT slice. Postoperative ethmoid labyrinth
emodeling. Anterior ethmoid roof detachment.
pportunistic deep fungal infections, after candidiasis and
spergillosis [3,5,7]. It is due to a ubiquitous (soil, bread
old, manure, rotting vegetables) mucoral fungus [1]. The
ater the diagnosis, the poorer the survival [5]. Facial and
erebral CT is the essential examination, and is systemat-
cally abnormal in rhinocerebral mucormycosis [1,8]. The
ost frequent radiologic signs are osteolysis, nodular thick-
ning of the sinus mucosa and absence of sinal ﬂuid level
1]. Other affected areas are the lateral wall of the nasal
ossae, septum, maxillary sinus, palate and orbit [1,3]. CT
etermines lesion extension towards the orbit and brain.
RI is more effective in assessing vascular (cavernous sinus
r internal carotid thrombosis) and cerebral invasion, and
an screen for cerebral involvement before onset of clini-
al signs [2]. Without treatment, mucormycosis is generally
atal [1—3,5,7], and even with early treatment recovery is
chieved in only 40% of cases [5]. Management comprises
ddressing predisposing factors, and rapid surgical debride-
ent (one factor of poor prognosis is more than 6 days’
CT
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delay in treatment initiation [5]). Among treatment options,
even partial resection of necrotic and/or infected tissue is
preferable to abstention, and antifungal medication is con-
sistently more effective when associated to surgery [3,5].
The partial functional endonasal surgery performed in the
present case, however, cannot be taken as a recommenda-
tion backed up by a high-level of evidence. The reference
antifungal is amphotericin B, to be administered at maxi-
mal dose despite its immediate side effects (fever, lowered
blood pressure, vomiting) and nephrotoxicity [3,5,7]. Clin-
ical and biological tolerance is better with lipid formulae:
liposomal (Ambisome®), colloidal (Amphocil®), or lipid com-
plex (Abelcet®), with the drawback that these can only be
administered intravenously. Despite its proven in vitro anti-
mucoral action, itraconazole was judged inappropriate in
2007 [3,5]. Posaconazole, available since July 2005 [9,10],
was used in oral form with success in the present case.
Caspofungin would seem to potentiate amphotericin B [10],
and efﬁcacy studies are in progress. Hyperbaric oxygen ther-
apy makes a useful contribution in case of resistance to
medico-surgical treatment [3].
Conclusion
Management of patients suffering from mucormycosis should
be multidisciplinary and initiated without delay. High-
dose Ambisome® (3 to 5mg/kg) should be prescribed for
1month, with early surgery and subsequent replacement
by posaconazole (800mg/day). There is no consensus as to
total treatment duration, which varies according to individ-
ual clinical evolution.
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